

April 3, 2006

Dainippon Sumitomo Pharma Co., Ltd.

Integration of US Subsidiaries and Renaming of European Subsidiary

Dainippon Sumitomo Pharma Co., Ltd. (President, Kenjiro Miyatake; Headquarters, Osaka, Japan) has announced the completed merger of its US subsidiaries with the formation of Dainippon Sumitomo Pharma America, Inc.

Likewise, it was also announced that Sumitomo Pharmaceuticals Europe Limited has been renamed to Dainippon Sumitomo Pharma Europe Ltd., with the former London business office having been closed.

Details of the wholly-owned subsidiaries are given below:

1. Corporate profile of Dainippon Sumitomo Pharma America, Inc.

(1) Trade name and trademark

Trade name: Dainippon Sumitomo Pharma America, Inc.

Trademark: Same as Dainippon Sumitomo Pharma Co., Ltd.

(2) Address

One Bridge Plaza, Suite 510, Fort Lee, NJ 07024-7102, U.S.A.

(3) Capitalization

\$600,000

(4) Effective date of merger

April 1, 2006

(5) Shareholder

Dainippon Sumitomo Pharma Co., Ltd. (100%)

(6) Board members

Chief Executive Officer (CEO) Shunsuke Sami

Chief Operating Officer (COO) Hiroshi Egawa

(7) Employees

Approximately 40

(8) Business

The development of ethical drugs (including the conduct of clinical trials), approval application activities, information gathering related to pharmaceutical and overseas affairs, sale of pharmaceuticals, and so forth in North America

(9) Merger structure

Dainippon Pharmaceutical U.S.A. Corporation is the surviving entity with Sumitomo Pharmaceuticals America, Ltd. having been dissolved.

2. Corporate profile of Dainippon Sumitomo Pharma Europe Ltd.

(1) Trade name and trademark

Trade name: Dainippon Sumitomo Pharma Europe Ltd.

Trademark: Same as Dainippon Sumitomo Pharma Co., Ltd.

(2) Address

Hamlet House, 77 Fulham Palace Road, London W6 8JA, U.K.

(3) Capitalization

£150,000

(4) Effective date of renaming

April 3, 2006

(5) Shareholder

Dainippon Sumitomo Pharma Co., Ltd. (100%)

(6) Board members

Chairman: Takeda Nobuo (Executive Officer, Dainippon Sumitomo Pharma Co., Ltd.)

President: Shunsuke Sami (CEO, Dainippon Sumitomo Pharma America, Inc.)

(7) Employees

Approximately 30

(8) Business

The development of ethical drugs (including the conduct of clinical trials), approval application activities, information gathering related to pharmaceutical and foreign affairs, sale of pharmaceuticals, and so forth in Europe.

For further information on this topic, please contact the following:

Public Relations, Dainippon Sumitomo Pharma Co., Ltd. (Phone: +81-(6)-6203-1407).